{"id":"placebo-to-dor","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Delta opioid receptors (DOR) are G-protein coupled receptors involved in pain modulation, mood regulation, and neuroprotection. Agonism at these receptors can produce analgesia through spinal and supraspinal mechanisms while potentially offering a different safety and abuse liability profile compared to mu opioid receptor agonists. This mechanism may provide pain relief with reduced respiratory depression and addiction potential.","oneSentence":"DOR is a delta opioid receptor agonist that activates delta opioid receptors to modulate pain signaling and potentially provide analgesic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:28:42.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain (investigational)"}]},"trialDetails":[{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT07296614","phase":"PHASE3","title":"Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-25","conditions":"Diminished Ovarian Reserve (DOR), Infertility","enrollment":320},{"nctId":"NCT05630755","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-17","conditions":"HIV-1 Infection","enrollment":514},{"nctId":"NCT05705349","phase":"PHASE3","title":"DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-08","conditions":"HIV-1 Infection","enrollment":537},{"nctId":"NCT07142187","phase":"NA","title":"The Clinical Trial of Electro-thumbtack Needle on Live Birth Rate in Patients With Ovarian Reserve Dysfunction (DOR)","status":"NOT_YET_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-10-01","conditions":"Diminished Ovarian Reserve (DOR)","enrollment":368},{"nctId":"NCT06794047","phase":"NA","title":"The Effect of VitC on IVF Outcome of DOR Patients","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-03-17","conditions":"Diminished Ovarian Reserve, IVF Outcomes","enrollment":1100},{"nctId":"NCT04233216","phase":"PHASE3","title":"Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-03-18","conditions":"HIV-1 Infection","enrollment":35},{"nctId":"NCT06617247","phase":"EARLY_PHASE1","title":"Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2024-12-01","conditions":"Burnout Syndrome","enrollment":26},{"nctId":"NCT04470050","phase":"PHASE1, PHASE2","title":"Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2020-06-09","conditions":"Opioid Withdrawal","enrollment":225},{"nctId":"NCT03272347","phase":"PHASE2","title":"Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-27","conditions":"HIV-1 Infection","enrollment":123},{"nctId":"NCT00979953","phase":"PHASE2","title":"Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-10","conditions":"Osteoarthritis of the Knee","enrollment":408},{"nctId":"NCT01058642","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-01","conditions":"Postherpetic Neuralgia","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to DOR","genericName":"Placebo to DOR","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DOR is a delta opioid receptor agonist that activates delta opioid receptors to modulate pain signaling and potentially provide analgesic effects. Used for Chronic pain (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}